P02.13 Identifying pathophysiological features of mouse tumors using imaging mass cytometry

April, 04, 2024 | Select Oncology Journal Articles


Mouse tumor models have greatly enhanced our understanding of tumorigenesis and are widely utilized as the preferred model organism for cancer studies and preclinical drug testing. The ability to evaluate the multiparametric response in the tumor micro-environment (TME) is crucial to predict therapeutic drug efficacy. Particularly, assessment of immunological and oncological processes that dictate tumor growth, metastasis, and immune response are essential for identifying candidates for further clinical evaluation.

Materials and Methods

Imaging Mass Cytometry™ (IMC™) permits analysis of 40-plus distinct tissue and cellular markers simultaneously on tumor samples, providing a thorough evaluation of the spatial landscape of the TME. Application of IMC to study cancer has facilitated important discoveries regarding the interplay of tumor and immune cells in the TME. Here, we introduce the Standard BioTools™ Maxpar® OnDemand Mouse Immuno-Oncology IMCPanel Kit (PN 9100005) designed for high-parameter preclinical immuno-oncology studies.


Through systematic selection of mouse antibodies from both the Maxpar catalog and from Maxpar OnDemand™, we have created panel kits that permit qualitative and quantitative evaluation of critical tumor pathophysiological parameters. This poster describes the design and application of an IMC panel consisting of 4 modular subpanels and defines their performance on multiple mouse tumor models. Furthermore, we present a consolidated single-cell analysis (SCA) pipeline by combining the panel kit with the Maxpar IMC Cell Segmentation Kit (ICSK, PN201500) and present quantitative evaluation of the cellular and structural landscape of mouse non-small-cell lung cancer (NSCLC), B cell lymphoma, colon adenocarcinoma, and renal carcinoma TME.


Overall, application of the MouseImmuno-Oncology Panel successfully defines the tissue architecture of the TME, metastatic and growth potential of tumor cells, and immune cell phenotype and activation in mouse tumors.

Q. Raza: A. Employment (full or part-time); Significant; Standard BioTools. L. Lim: A. Employment (full or part-time); Significant; Standard BioTools. T. Pfister: A. Employment (full or part-time); Significant; Standard BioTools. N. Zabinyakov: A. Employment (full or part-time); Significant; Standard BioTools. C. Loh: A. Employment (full or part-time); Significant; Standard BioTools.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy